Eisai files for Japanese approval of Biocompatibles' embolic beads
This article was originally published in Scrip
Following the exercise of an option earlier this year, Eisai has now made an approval filing in Japan for a microspheric bead product licensed from Biocompatibles International, for the treatment of hepatocellular carcinoma (HCC).
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.